Cargando…
The Potential of Lisosan G as a Possible Treatment for Glaucoma
Lisosan G (LG), a fermented powder obtained from whole grains, is a nutritional supplement containing a variety of metabolites with documented antioxidant properties. We have recently demonstrated that orally administered LG protects diabetic rodent retinas from oxidative stress, inflammation, apopt...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355587/ https://www.ncbi.nlm.nih.gov/pubmed/34393798 http://dx.doi.org/10.3389/fphar.2021.719951 |
_version_ | 1783736793235980288 |
---|---|
author | Amato, Rosario Rossino, Maria Grazia Cammalleri, Maurizio Timperio, Anna Maria Fanelli, Giuseppina Dal Monte, Massimo Pucci, Laura Casini, Giovanni |
author_facet | Amato, Rosario Rossino, Maria Grazia Cammalleri, Maurizio Timperio, Anna Maria Fanelli, Giuseppina Dal Monte, Massimo Pucci, Laura Casini, Giovanni |
author_sort | Amato, Rosario |
collection | PubMed |
description | Lisosan G (LG), a fermented powder obtained from whole grains, is a nutritional supplement containing a variety of metabolites with documented antioxidant properties. We have recently demonstrated that orally administered LG protects diabetic rodent retinas from oxidative stress, inflammation, apoptosis, blood-retinal barrier disruption, and functional damage. Here, we investigated whether LG may exert protective effects in a model of glaucoma and measured the amounts of selected LG components that reach the retina after oral LG administration. Six-month-old DBA/2J mice were given an aqueous LG solution in place of drinking water for 2 mo. During the 2 mo of treatment with LG, the intraocular pressure (IOP) was monitored and the retinal ganglion cell (RGC) functional activity was recorded with pattern-electroretinography (PERG). At the end of the 2-mo period, the expression of oxidative stress and inflammatory markers was measured with qPCR, and RGC survival or macroglial activation were assessed with immunofluorescence. Alternatively, LG was administered by gavage and the concentrations of four of the main LG components (nicotinamide, gallic acid, 4-hydroxybenzoic acid, and quercetin) were measured in the retinas in the following 24 h using mass spectrometry. LG treatment in DBA/2J mice did not influence IOP, but it affected RGC function since PERG amplitude was increased and PERG latency was decreased with respect to untreated DBA/2J mice. This improvement of RGC function was concomitant with a significant decrease of both oxidative stress and inflammation marker expression, of RGC loss, and of macroglial activation. All four LG metabolites were found in the retina, although with different proportions with respect to the amount in the dose of administered LG, and with different temporal profiles in the 24 h following administration. These findings are consistent with neuroenhancing and neuroprotective effects of LG in glaucoma that are likely to derive from its powerful antioxidant properties. The co-occurrence of different metabolites in LG may provide an added value to their beneficial effects and indicate LG as a basis for the potential treatment of a variety of retinal pathologies. |
format | Online Article Text |
id | pubmed-8355587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83555872021-08-12 The Potential of Lisosan G as a Possible Treatment for Glaucoma Amato, Rosario Rossino, Maria Grazia Cammalleri, Maurizio Timperio, Anna Maria Fanelli, Giuseppina Dal Monte, Massimo Pucci, Laura Casini, Giovanni Front Pharmacol Pharmacology Lisosan G (LG), a fermented powder obtained from whole grains, is a nutritional supplement containing a variety of metabolites with documented antioxidant properties. We have recently demonstrated that orally administered LG protects diabetic rodent retinas from oxidative stress, inflammation, apoptosis, blood-retinal barrier disruption, and functional damage. Here, we investigated whether LG may exert protective effects in a model of glaucoma and measured the amounts of selected LG components that reach the retina after oral LG administration. Six-month-old DBA/2J mice were given an aqueous LG solution in place of drinking water for 2 mo. During the 2 mo of treatment with LG, the intraocular pressure (IOP) was monitored and the retinal ganglion cell (RGC) functional activity was recorded with pattern-electroretinography (PERG). At the end of the 2-mo period, the expression of oxidative stress and inflammatory markers was measured with qPCR, and RGC survival or macroglial activation were assessed with immunofluorescence. Alternatively, LG was administered by gavage and the concentrations of four of the main LG components (nicotinamide, gallic acid, 4-hydroxybenzoic acid, and quercetin) were measured in the retinas in the following 24 h using mass spectrometry. LG treatment in DBA/2J mice did not influence IOP, but it affected RGC function since PERG amplitude was increased and PERG latency was decreased with respect to untreated DBA/2J mice. This improvement of RGC function was concomitant with a significant decrease of both oxidative stress and inflammation marker expression, of RGC loss, and of macroglial activation. All four LG metabolites were found in the retina, although with different proportions with respect to the amount in the dose of administered LG, and with different temporal profiles in the 24 h following administration. These findings are consistent with neuroenhancing and neuroprotective effects of LG in glaucoma that are likely to derive from its powerful antioxidant properties. The co-occurrence of different metabolites in LG may provide an added value to their beneficial effects and indicate LG as a basis for the potential treatment of a variety of retinal pathologies. Frontiers Media S.A. 2021-07-28 /pmc/articles/PMC8355587/ /pubmed/34393798 http://dx.doi.org/10.3389/fphar.2021.719951 Text en Copyright © 2021 Amato, Rossino, Cammalleri, Timperio, Fanelli, Dal Monte, Pucci and Casini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Amato, Rosario Rossino, Maria Grazia Cammalleri, Maurizio Timperio, Anna Maria Fanelli, Giuseppina Dal Monte, Massimo Pucci, Laura Casini, Giovanni The Potential of Lisosan G as a Possible Treatment for Glaucoma |
title | The Potential of Lisosan G as a Possible Treatment for Glaucoma |
title_full | The Potential of Lisosan G as a Possible Treatment for Glaucoma |
title_fullStr | The Potential of Lisosan G as a Possible Treatment for Glaucoma |
title_full_unstemmed | The Potential of Lisosan G as a Possible Treatment for Glaucoma |
title_short | The Potential of Lisosan G as a Possible Treatment for Glaucoma |
title_sort | potential of lisosan g as a possible treatment for glaucoma |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355587/ https://www.ncbi.nlm.nih.gov/pubmed/34393798 http://dx.doi.org/10.3389/fphar.2021.719951 |
work_keys_str_mv | AT amatorosario thepotentialoflisosangasapossibletreatmentforglaucoma AT rossinomariagrazia thepotentialoflisosangasapossibletreatmentforglaucoma AT cammallerimaurizio thepotentialoflisosangasapossibletreatmentforglaucoma AT timperioannamaria thepotentialoflisosangasapossibletreatmentforglaucoma AT fanelligiuseppina thepotentialoflisosangasapossibletreatmentforglaucoma AT dalmontemassimo thepotentialoflisosangasapossibletreatmentforglaucoma AT puccilaura thepotentialoflisosangasapossibletreatmentforglaucoma AT casinigiovanni thepotentialoflisosangasapossibletreatmentforglaucoma AT amatorosario potentialoflisosangasapossibletreatmentforglaucoma AT rossinomariagrazia potentialoflisosangasapossibletreatmentforglaucoma AT cammallerimaurizio potentialoflisosangasapossibletreatmentforglaucoma AT timperioannamaria potentialoflisosangasapossibletreatmentforglaucoma AT fanelligiuseppina potentialoflisosangasapossibletreatmentforglaucoma AT dalmontemassimo potentialoflisosangasapossibletreatmentforglaucoma AT puccilaura potentialoflisosangasapossibletreatmentforglaucoma AT casinigiovanni potentialoflisosangasapossibletreatmentforglaucoma |